Received Aug 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
first dose of Shingrix in 2023 and then a second dose was given in April 2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (a patient received the first dose of Shingrix in 2023). In APR-2025, the patient received the 2nd dose of Shingrix. In APR-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: first dose of Shingrix in 2023 and then a second dose was given in April 2025). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK receipt date: 25-JUL-2025 A pharmacist mentioned that a patient received the first dose of Shingrix in 2023 and then a second dose was given in April 2025, which led to drug dose administration interval too long. The healthcare professional (HCP) asked if the patient was 100 percent protected because today, the patient was at the clinic requesting a third dose. No further details were provided. The reporter was consented to follow up.